Koers Threshold Pharmaceuticals, Inc. Nasdaq
Aandelen
US8858072064
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 12,7 mln. 11,91 mln. | Omzet 2025 * | 1,37 mln. 1,28 mln. | Marktkapitalisatie | 10,93 mln. 10,25 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -22 mln. -20,62 mln. | Nettowinst (verlies) 2025 * | -34 mln. -31,87 mln. | EV/omzet 2024 * | 0,86 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 8 x |
K/w-verhouding 2024 * |
-0,51
x | K/w-verhouding 2025 * |
-0,42
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,04% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eric Poma
CEO | Chief Executive Officer | 52 | 01-01-00 |
Jason Kim
PSD | President | 49 | 01-01-10 |
Kristen Quigley
COO | Chief Operating Officer | 53 | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Eric Poma
CEO | Chief Executive Officer | 52 | 01-01-00 |
Harold Selick
CHM | Chairman | 69 | 01-08-17 |
David Hoffmann
BRD | Director/Board Member | 79 | 01-08-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-15,84% | 21,4 mld. | |
-10,05% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,65% | 16,09 mld. | |
+4,39% | 13,83 mld. | |
+31,35% | 11,97 mld. |